TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$86 Million

BioLife Solutions

Follow-on Offering

Lead Left Bookrunner, July 2020

BioLife Solutions

BioLife Solutions develops, manufactures and markets bioproduction tools to the cell and gene therapy (“C&GT”) industry. BioLife’s customers use the Company’s products to maintain the health and function of biologic material during sourcing, manufacturing, storage, and distribution of cells and tissues. BioLife’s four main product lines include biopreservation media, automated thawing devices, cloud connected “smart” shipping containers and freezer and storage technology. Biolife’s biopreservation products, HypoThermosol and CytoStor, are formulated to mitigate preservation-induced, delayed-onset cell damage and death, which result when cells and tissues are subjected to reduced temperatures. The technology can provide the Company’s C&GT customers with significant shelf life extension of biologic source material and final cell products, and can also greatly improve post-preservation cell and tissue viability and function. The Company estimates that its biopreservation media products have been incorporated in over 400 customer clinical applications.